ONCBeiGeneRunning, no new patients
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma · Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Small Lymphocytic Lymphoma · Relapsed Chronic Lymphocytic Leukemia
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jan 2025, none posted yet
Counts until it's fixed
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 2
- Patients
- 100 (final count)
- Started
- Oct 25, 2022
- Main results expected
- Jan 24, 2025
- Fully finished
- Aug 25, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
Measured over: Up to 2 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-01-24, no fading
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05479994 · record last updated 2026-03-04 · checked 2026-11-09 15:47 UTC